Previous Page  9 / 14 Next Page
Information
Show Menu
Previous Page 9 / 14 Next Page
Page Background

M a y 0 9 - 1 0 , 2 0 1 9

S t o c k h o l m , S w e d e n

Page 41

Journal of Organic & Inorganic Chemistry

ISSN: 2472-1123

Advanced Chemistry 2019

2

nd

European Congress on

Advanced Chemistry

C

ancer is a dreadful disease and any practical solution in combating this disease is of paramount importance to public health.

Cancer patients have burdened by drug induced toxic side effects, and no one turned to seek help from the complementary and

alternative medicine hoping for a better cure. Research on platinum based drugs and non-platinum based drugs is a multi-million dollar

industry in USA and there is every need to produce safe drugs for the cure of this monstrous disease. Flavonoids have a long history

of use in traditional medicines in many cultures. The phytochemical, curcumin is one of the major dietary flavonoid, belonging to a

group of flavonol. Curcumin is a natural polyphenol. It is highly potential molecule capable of preventing and treating various cancers.

Various dietary chemo preventive agents, turmeric powder or its extract are broadly used as therapeutic preparations in Indian system of

medicine. We provide a summarized synthesis and structural determination of curcumin oxime, curcumin thiosemicarbazone derivative

of gold (III) complex. These analogs are used for prevention of cancer tumor progression and treatment of human malignancies. A

pharmacologic agent is observed for treating and/or preventing cancer, among other diseases and conditions, and particularly breast,

prostate, and pancreatic cancer, in humans and animals. The novel pharmacologic agent is an isoflavonoid or isoflavonoid mimetic

covalently attached to a cytotoxic pharmacophore that, preferably has the ability to conjugate with a metal salt to form a more potent

metal complex, particularly a Au (III) complex and other complexes of platinum, palladium, ruthenium, copper etc. My talk would mainly

encompass different transition metal complexes/organometallic compounds that are presently used as drugs, especially anticancer

and anti-HIV drugs, apart from anti-inflammatory, antimicrobial, antibacterial and diseases like arthritis and Parkinson’s disease etc.

The talk would mainly focus on the use of medicinal chemistry and its application to drug design and development in pharmaceutical

industry, especially transition metal complexes and organometallic compounds viz. gold, platinum, palladium and ruthenium apart from

copper, cobalt, iron, nickel, zinc, cadmium etc. The main emphasis of my talk would be on different class of ligands, their Schiff’s bases

and transition metal complexes especially Au, Pt, Pd and Ru, with the main aim of designing, developing very novel small molecules,

as possible and extremely potential candidates as anti-cancer and anti-HIV drugs. The talk would provide an overview of current

programs being undertaken in our laboratories, especially focused on the development of potent ligands capable of recognizing binding

sites and diverse strategies employed by my group for elucidation of anti-cancer and anti-HIV drug leads to circumvent the problem

caused by cis-platin. We have synthesized and characterized several phytochemicals from traditional medicinal plants and isolated

some phytochemicals and made the corresponding oximes, thiosemicarbazones and substituted thiosemicarbazones as ligands and

synthesized, characterized, structurally elucidated their transition metal complexes especially with gold, platinum, palladium, ruthenium,

copper etc. and studied their anticancer activity, nuclease activity etc. and tested their potential as anticancer drugs. The main aim of

our extensive/preclinical pharmaceutical development program is to investigate the use of these extremely novel small molecules-metal

complexes/compounds of phytochemicals, flavanoids etc., which have very interesting structural features and properties and hence are

excellent candidates as anti-cancer and anti-HIV drugs. The main aim of our research is design, development and synthesis of transition

metal complexes/organometallic compounds that would certainly help to bring this force of nature from bench to bedside and enhance

cancer killing with less toxic effects and would certainly lead to initiation of clinical trials.

pk6030882@gmail.com

Transition metal complexes/organometallic

compounds as anticancer/anti HIV drugs in

pharmaceutical industry

Prakash Kinthada

National Institute of Medical Sciences (NIMS), India

J Org Inorg Chem 2019, Volume:5

DOI: 10.21767/2472-1123-C2-024